Berkeley Research Group appoints a new Director

Edward Buthusiem will join the Health Analytics Practice at the US firm

Berkeley Research Group, an expert services firm has Edward Buthusiem as a Director based in Philadelphia and a member of the firm’s Health Analytics Practice.

Buthusiem advises executive management and general counsels on a variety of strategic business and operational issues. He is an expert in mergers and acquisitions, technology licensing transactions, and innovation.

Before joining BRG, Buthusiem was General Counsel of Danaher Corporation’s global medical device business, and he held various senior executive positions at GlaxoSmithKline for more than 20 years.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Manufacturing

Servier opens new €86m biologics production facility in Loiret, France

The company's Bio-S facility will be responsible for the production of biological medicines stemming from its R&D pipeline for preclinical and clinical studies
Manufacturing

Leybold launches Duradry vacuum pump for harsh processes

Advanced technology designed for reliability and efficiency
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Digital

Why CGT manufacturers should automate the production process

Cell and gene therapies can be highly complex and time-consuming to produce at scale; full robotic automation could help biologics manufacturers to make processes more space, personnel and cost efficient
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Subscribe now